JFSF Vol 8, No 1, March 2023, p.44-52
doi: 10.22540/JFSF-08-044
PDF  
Review Article
Sarcopenia in Rheumatoid arthritis. A narrative review
Dimitra Moschou1, Michail Krikelis1, Christos Georgakopoulos1, Evangelia Mole1, Efstathios Chronopoulos2, Symeon Tournis2, Clio Mavragani3, Konstantinos Makris4, Ismene Dontas2, Susana Gazi1
- Rheumatology Department, KAT General Hospital, Attica, Greece
- Laboratory for Research of the Musculoskeletal System “Theodoros Garofalidis”, School of Medicine, National and Kapodistrian University of Athens, KAT General Hospital, Attica, Greece
- Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Attica, Greece
- Clinical Biochemistry Department, KAT General Hospital, Attica, Greece
Keywords: Autoimmune disease, Inflammation, Rheumatoid arthritis, Sarcopenia
Abstract
Sarcopenia was recently identified as an entity in the ICD-10 classification of October 2016. According to the recommendation of the European Working Group on Sarcopenia in Older People (EWGSOP2), sarcopenia is defined as low muscle strength and low muscle mass, while physical performance is used to categorize the severity of sarcopenia. In recent years, sarcopenia has become increasingly common in younger patients with autoimmune diseases such as Rheumatoid arthritis (RA). Due to the chronic inflammation caused by RA, patients have reduced physical activity, immobility, stiffness, and joint destruction and all of that lead to the loss of muscle mass, muscle strength, disability and significantly lowering the patients’ quality of life. This article is a narrative review about sarcopenia in RA, with a special focus in its pathogenesis and management.
Share this article on:
Twitter
LinkedIn
Facebook